as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹1,788.4
Change
+0.3 (0.02%)
Open
₹1,788.1
Prev. Close
₹1,788.1
Day High
₹1,814.3
Day Low
₹1,772.1
Volume Analysis
Traded
459,393
Delivered
192,602
Delivery %
41.93%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong operating margin (29.0%)
Weaknesses (1)
- •Promoter holding is falling
Opportunities (2)
- •Strong 3-year revenue growth (21.7%)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹1,853.3 | ₹1,833.8 | ₹1,811.1 | ₹1,791.6 | ₹1,768.9 | ₹1,749.4 | ₹1,726.7 |
| Fibonacci | ₹1,833.8 | ₹1,817.68 | ₹1,807.72 | ₹1,791.6 | ₹1,775.48 | ₹1,765.52 | ₹1,749.4 |
| Camarilla | ₹1,800.01 | ₹1,796.14 | ₹1,792.27 | ₹1,791.6 | ₹1,784.53 | ₹1,780.66 | ₹1,776.8 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+98.66%
1 Week
-6.13%
1 Month
+28.33%
3 Months
+22.71%
6 Months
+60.57%
1 Year
+104.65%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹217.01
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
12.87%
Net margin 15.86% × asset turnover 0.52x × equity multiplier 1.56x
Company Overview
Sector
Healthcare
Market Cap
₹41,003 Cr
P/E (TTM)
107.0
ROE
15.4%
Book Value
₹127.0
Face Value
₹1.0
Source: Screener.in (Consolidated figures) — data as of 14 Nov 2026. Not investment advice.
TopFund Analysis
Sai Life Sciences Limited holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 74/100. The strongest factor is Financial Strength (100/100), while Valuation (0/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (29.0%); promoter holding is falling. Strong 3-year revenue growth (21.7%).
TopFund Score — Fundamentals Quality
74/100 — GoodData confidence: 78/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has delivered good profit growth of 42.2% CAGR over last 5 years
- −Stock is trading at 15.2 times its book value
- −Though the company is reporting repeated profits, it is not paying out dividend
- −Company has a low return on equity of 12.7% over last 3 years.
- −Working capital days have increased from 49.2 days to 69.8 days
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
India Ratings upgraded Sai Life Sciences' long-term bank loan rating to IND AA; short-term rating affirmed at IND A1+.
Transcripts of Earnings call organized on 06th November 2026
CRISIL confirms Sai Life Sciences fully utilised Rs 9,500 million IPO proceeds by September 30, 2026.
Newspaper Publication of Un-audited Standalone and Consolidated Financial Results for the Second Quarter and Half Year Ended 30th September 2026
Audio recording of Q2 FY2026-27 earnings conference call shared on 6 November 2026.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 384 | 439 | 280 | 396 | 440 | 580 | 496 | 537 | 556 | 602 | 554 | 659 |
| Expenses + | 287 | 315 | 254 | 293 | 320 | 422 | 375 | 392 | 369 | 426 | 406 | 472 |
| Operating Profit | 96 | 125 | 26 | 102 | 120 | 158 | 121 | 146 | 188 | 177 | 148 | 186 |
| OPM % | 25.0% | 28.0% | 9.0% | 26.0% | 27.0% | 27.0% | 24.0% | 27.0% | 34.0% | 29.0% | 27.0% | 28.0% |
| Other Income + | 11 | 3 | 8 | 10 | 9 | 10 | 10 | 15 | 0 | 16 | 4 | 4 |
| Interest | 23 | 21 | 21 | 21 | 23 | 11 | 12 | 9 | 10 | 8 | 8 | 11 |
| Depreciation | 31 | 31 | 31 | 36 | 34 | 37 | 38 | 40 | 44 | 45 | 46 | 48 |
| Profit before tax | 53 | 76 | -18 | 55 | 72 | 119 | 81 | 112 | 134 | 139 | 98 | 131 |
| Tax % | 25.0% | 26.0% | -25.0% | 25.0% | 25.0% | 26.0% | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% |
| Net Profit + | 40 | 56 | -14 | 42 | 54 | 88 | 60 | 84 | 100 | 104 | 73 | 98 |
| EPS in Rs | — | — | — | — | 3 | 4 | 3 | 4 | 5 | 5 | 3 | 5 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | — | — | — | — | 15 | 32 | 77 | 36 | 27 | 4 | 12 | 23 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Sales + | 695 | 726 | 760 | 870 | 1,217 | 1,465 | 1,695 | 2,192 | 2,371 |
| Expenses + | 520 | 558 | 593 | 743 | 1,048 | 1,178 | 1,285 | 1,559 | 1,673 |
| Operating Profit | 176 | 168 | 167 | 126 | 169 | 287 | 410 | 634 | 699 |
| OPM % | 25.0% | 23.0% | 22.0% | 15.0% | 14.0% | 20.0% | 24.0% | 29.0% | 29.0% |
| Other Income + | 6 | 18 | 27 | 28 | 27 | 29 | 35 | 40 | 23 |
| Interest | 24 | 22 | 33 | 54 | 81 | 88 | 78 | 41 | 36 |
| Depreciation | 44 | 55 | 80 | 90 | 99 | 119 | 139 | 167 | 183 |
| Profit before tax | 113 | 109 | 82 | 10 | 16 | 109 | 228 | 466 | 503 |
| Tax % | 35.0% | 30.0% | 25.0% | 36.0% | 39.0% | 24.0% | 25.0% | 25.0% | — |
| Net Profit + | 73 | 76 | 61 | 6 | 10 | 83 | 170 | 349 | 376 |
| EPS in Rs | — | — | — | — | — | — | 8 | 16 | 18 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 1,117.0% | 676.0% | 0.0% | 0.0% | 0.0% | — |
| Sales growth | — | 4 | 5 | 14 | 40 | 20 | 16 | 29 | 16 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Reserves | 703 | 778 | 845 | 861 | 870 | 957 | 2,108 | 2,463 | 2,667 |
| Borrowings + | 249 | 304 | 637 | 752 | 933 | 928 | 352 | 288 | 620 |
| Other Liabilities + | 247 | 312 | 318 | 527 | 358 | 359 | 665 | 841 | 895 |
| Total Liabilities | 1,215 | 1,410 | 1,817 | 2,157 | 2,179 | 2,262 | 3,146 | 3,613 | 4,202 |
| Fixed Assets + | 373 | 641 | 701 | 751 | 1,037 | 1,180 | 1,488 | 1,815 | 2,045 |
| CWIP | 116 | 91 | 246 | 410 | 151 | 107 | 124 | 270 | 560 |
| Investments | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 50 | 52 |
| Other Assets + | 726 | 679 | 870 | 997 | 989 | 973 | 1,531 | 1,477 | 1,545 |
| Total Assets | 1,215 | 1,410 | 1,817 | 2,157 | 2,179 | 2,262 | 3,146 | 3,613 | 4,202 |
| Equity Capital | 16 | 16 | 17 | 18 | 18 | 18 | 21 | 21 | 21 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 129 | 116 | -36 | 105 | 219 | 263 | 314 | 509 |
| Cash from Investing Activity + | -158 | -262 | -260 | -102 | -99 | -191 | -536 | -395 |
| Cash from Financing Activity + | 268 | -4 | 296 | 72 | -201 | -95 | 301 | -124 |
| Net Cash Flow | 239 | -150 | -1 | 75 | -80 | -24 | 79 | -9 |
| Free Cash Flow | -28 | -157 | -298 | -102 | 148 | 82 | -55 | -83 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 90 | 81 | -13 | 90 | 132 | 96 | 82 | 86 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|
| Public | 41.08% | 39.21% | 28.64% | 12.65% | 12.49% | 12.69% | 13.11% | 13.25% |
| Promoters | 35.23% | 35.16% | 35.15% | 34.95% | 34.7% | 34.61% | 34.53% | 34.5% |
| FII | 11.72% | 12.36% | 14.57% | 22.5% | 21.41% | 21.17% | 19.65% | 19.91% |
| DII | 11.95% | 13.26% | 21.64% | 29.92% | 31.41% | 31.54% | 32.71% | 32.32% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Sai Life Sciences Limited (this stock) | 41,003 | 107.0 | 15.19 | 15.4% |
| Ajanta Pharma Limited | 41,393 | 32.8 | 8.51 | 27.1% |
| Global Health Limited | 38,864 | 60.0 | 8.97 | 15.2% |
| Narayana Hrudayalaya Ltd. | 37,889 | 41.8 | 7.57 | 20.5% |
| Emcure Pharmaceuticals L | 44,370 | 39.9 | 8.29 | 20.1% |
| Glaxosmithkline Pharma Lt | 45,576 | 40.2 | 24.22 | 45.6% |
| Ipca Laboratories Ltd | 46,508 | 32.3 | 5.36 | 15.7% |
Which Mutual Funds Hold Sai Life Sciences Limited?
Frequently Asked Questions about Sai Life Sciences Limited
Sai Life Sciences Limited (SAILIFE) closed at ₹1,788.4 on NSE on 19 November 2026, up 0.3 (0.02%) from the previous close.
Sai Life Sciences Limited trades on the NSE (National Stock Exchange of India) under the symbol SAILIFE.
Sai Life Sciences Limited has a trailing twelve-month P/E (price-to-earnings) ratio of 107.0.
Sai Life Sciences Limited has a dividend yield of 0.0%.
Sai Life Sciences Limited's 52-week high is ₹1,955.0 and its 52-week low is ₹784.0.
Sai Life Sciences Limited has a market capitalisation of ₹41,003 crore.
Sai Life Sciences Limited has a TopFund Quality Score of 74/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Sai Life Sciences Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.